Skip to main content
Contact Us
Subscribe
E-Edition
72°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Theralase Technologies Inc
(OP:
TLTFF
)
0.1518
-0.0106 (-6.53%)
Streaming Delayed Price
Updated: 1:50 PM EDT, Mar 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Theralase Technologies Inc
< Previous
1
2
Next >
Theralase(R) Expands Clinical Team
May 02, 2024
Via
ACCESSWIRE
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
April 24, 2024
Via
ACCESSWIRE
Theralase(R) Granted Canadian Cancer Vaccine Patent
April 05, 2024
Via
ACCESSWIRE
Theralase(R) Release's 4Q2023 Interim Financial Statements
March 27, 2024
Via
ACCESSWIRE
Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
March 26, 2024
Via
ACCESSWIRE
Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study
October 23, 2023
Via
ACCESSWIRE
Theralase(R) Provides Update on Bladder Cancer Clinical Study
October 16, 2023
Via
ACCESSWIRE
Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease
February 12, 2024
Via
ACCESSWIRE
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
February 08, 2024
Via
ACCESSWIRE
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
February 05, 2024
Via
ACCESSWIRE
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
January 15, 2024
Via
ACCESSWIRE
Theralase(R) Files US Patent for Enhanced Immunotherapy
October 05, 2023
Via
ACCESSWIRE
Theralase Release’s 3Q2023 Interim Financial Statements
November 29, 2023
Via
ACCESSWIRE
Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement
November 29, 2023
Via
ACCESSWIRE
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
November 17, 2023
Via
ACCESSWIRE
Theralase(R) Announces Brokered LIFE Financing
October 23, 2023
Via
ACCESSWIRE
Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)
September 29, 2023
Via
ACCESSWIRE
Theralase(R) Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer
September 27, 2023
Via
ACCESSWIRE
Theralase(R) Grants Stock Options
September 21, 2023
Via
ACCESSWIRE
Theralase(R) Closes Private Placement Equity Financing
September 07, 2023
Via
ACCESSWIRE
Theralase Release’s 2Q2023 Interim Financial Statements
August 29, 2023
Via
ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement Equity Financing
June 30, 2023
Via
ACCESSWIRE
Theralase(R) Announces Appointment of New Independent Director
June 06, 2023
Via
ACCESSWIRE
Theralase(R) Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements
May 30, 2023
Via
ACCESSWIRE
Theralase(R) Releases 1Q2023 Interim Financial Statements
May 30, 2023
Via
ACCESSWIRE
Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive Officer
May 24, 2023
Via
ACCESSWIRE
Theralase Provides Update on Phase II Bladder Cancer Study
May 10, 2023
Via
ACCESSWIRE
Theralase Release FY2020 Audited Financial Statements
April 28, 2021
TORONTO, ON / ACCESSWIRE / April 28, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and...
From
Theralase Technologies Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Theralase(R) Releases Quarterly Newsletter
April 27, 2021
TORONTO, ON / ACCESSWIRE / April 27, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and...
From
Theralase Technologies Inc.
Via
AccessWire
Exposures
Product Safety
Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus Vaccine
April 09, 2021
TORONTO, ON / ACCESSWIRE / April 9, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and...
From
Theralase Technologies Inc.
Via
AccessWire
Exposures
COVID-19
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
